Navigation Links
Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
Date:10/10/2008

MADISON, N.J., Oct. 10 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that the jury in the case of Danny Crowder (Individually and as Administrator of the Estate of Edna Faye Crowder) v. Wyeth in the Philadelphia Court of Common Pleas found in favor of Wyeth.

"We believe this unanimous verdict was supported by the evidence," says Bob Nicholas, an attorney from Reed Smith, who represented Wyeth. "While Mrs. Crowder's death was tragic, the medical evidence clearly demonstrated that her condition was unrelated to the diet drugs she used over ten years ago."

The trial began on September 29, 2008 before The Honorable Gary S. Glazer. The plaintiff alleged the wrongful death of Mrs. Crowder caused by Primary Pulmonary Hypertension (PPH) as a result of her use of the diet drug Pondimin(R), a drug once marketed by Wyeth. The Court had earlier ruled that plaintiff could not pursue punitive damages in this case.

The plaintiff was represented by the Clark Burnett law firm of Houston, Texas.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Wyeth Announces Increase in Common Stock Dividend
2. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
3. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
4. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
5. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
6. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
7. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
8. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
9. Wyeth Declares Common and Preferred Stock Dividends
10. Wyeth Pharmaceuticals Announces Organizational Change
11. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 6, 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... fourth quarter and fiscal year ended September 30, 2016. ... , , ... sciences and diagnostics company that develops and commercializes proprietary technologies and ... Achieved revenues of $1.4 million more than tripling prior ...
(Date:12/6/2016)... Collins, Colorado (PRWEB) , ... December 06, 2016 ... ... of dynamic aqueous plasma technology platforms, announced today that the company has engaged ... Master Research and Development Agreement (MRDA) with the CSU Office of the Vice ...
(Date:12/6/2016)... , Dec. 6, 2016  SRI International ... $150 million from the National Institutes of Health,s ... the Division of AIDS (NIAID-DAIDS) to support the ... non-vaccine pre-exposure (PreP) agents. Under the seven-year contract, ... product development services for candidate HIV-prevention products that ...
(Date:12/5/2016)... ... 2016 , ... This composition patent, U.S. Patent No. 9,499,637, ... composition claims are not limited to any particular process to make or use ... fibers, graphene, and other materials. A continuation application, U.S. Patent App. No. ...
Breaking Biology Technology:
(Date:11/22/2016)... -- According to the new market research report "Biometric System ... Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and ... expected to grow from USD 10.74 Billion in 2015 to reach USD ... 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
Breaking Biology News(10 mins):